FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma
October 18, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for nivolumab to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection, according to Bristol-Myers Squibb ...Leggi tutto